Francisco José Bermúdez-Jiménez

Dr. Francisco José Bermúdez-Jiménez

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2018 in Circulation
Verified
Journal Article
Closed access
PDF file
FBFrancisco José Bermúdez-Jiménez
Francisco José Bermúdez-Jiménez
VCVíctor Carriel
Víctor Carriel
Andreas BrodehlAndreas Brodehl
Andreas Brodehl
MAMiguel Alaminos
Miguel Alaminos
ACAntonio Campos
Antonio Campos
JJJuan Jiménez-Jáimez
Juan Jiménez-Jáimez
Background: Desmin ( DES ) mutations cause severe skeletal and cardiac muscle disease with heterogeneous phenotypes. Recently, DES mutations were described in patients with inherited arrhythmogenic right ventricular cardiomyopathy/dysplasia, although their cellular and molecular pathomechanisms are not precisely known. Our aim is to describe clinically and functionally the novel DES -p.Glu401Asp mutation as a cause of inherited left ventricular arrhythmogenic cardiomyopathy/dysplasia. Methods: We identified the novel DES mutation p.Glu401Asp in a large Spanish family with inherited left ventricular arrhythmogenic cardiomyopathy/dysplasia and a high incidence of adverse cardiac events. A full clinical evaluation was performed on all mutation carriers and noncarriers to establish clinical and genetic cosegregation. In addition, desmin, and intercalar disc–related proteins expression were histologically analyzed in explanted cardiac tissue affected by the DES mutation. Furthermore, mesenchymal stem cells were isolated and cultured from 2 family members with the DES mutation (1 with mild and 1 with severe symptomatology) and a member without the mutation (control) and differentiated ex vivo to cardiomyocytes. Then, important genes related to cardiac differentiation and function were analyzed by real-time quantitative polymerase chain reaction. Finally, the p.Glu401Asp mutated DES gene was transfected into cell lines and analyzed by confocal microscopy. Results: Of the 66 family members screened for the DES -p.Glu401Asp mutation, 23 of them were positive, 6 were obligate carriers, and 2 were likely carriers. One hundred percent of genotype-positive patients presented data consistent with inherited arrhythmogenic cardiomyopathy/dysplasia phenotype with variable disease severity expression, high-incidence of sudden cardiac death, and absence of skeletal myopathy or conduction system disorders. Immunohistochemistry was compatible with inherited arrhythmogenic cardiomyopathy/dysplasia, and the functional study showed an abnormal growth pattern and cellular adhesion, reduced desmin RNA expression, and some other membrane proteins, as well, and desmin aggregates in transfected cells expressing the mutant desmin. Conclusions: The DES -p.Glu401Asp mutation causes predominant inherited left ventricular arrhythmogenic cardiomyopathy/dysplasia with a high incidence of adverse clinical events in the absence of skeletal myopathy or conduction system disorders. The pathogenic mechanism probably corresponds to an alteration in desmin dimer and oligomer assembly and its connection with membrane proteins within the intercalated disc.

8 November 2019 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
DSDiego Segura-Rodríguez
Diego Segura-Rodríguez
FBFrancisco José Bermúdez-Jiménez
Francisco José Bermúdez-Jiménez
Víctor CarrielVíctor Carriel
Víctor Carriel
SLSilvia López-Fernández
Silvia López-Fernández
MGMercedes González-Molina
Mercedes González-Molina
JJJuan Jiménez-Jáimez
Juan Jiménez-Jáimez
Aims: Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a life-threatening entity with a highly heterogeneous genetic background. Cardiac magnetic resonance (CMR) imaging can identify fibrofatty scar by late gadolinium enhancement (LGE). Our aim is to investigate genotype–phenotype correlation in ARVC/D mutation carriers, focusing on CMR-LGE and myocardial fibrosis patterns. Methods and results: A cohort of 44 genotyped patients, 33 with definite and 11 with borderline ARVC/D diagnosis, was characterized using CMR and divided into groups according to their genetic condition (desmosomal, non-desmosomal mutation, or negative). We collected information on cardiac volumes and function, as well as LGE pattern and extension. In addition, available ventricular myocardium samples from patients with pathogenic gene mutations were histopathologically analysed. Half of the patients were women, with a mean age of 41.6 ± 17.5 years. Next-generation sequencing identified a potential pathogenic mutation in 71.4% of the probands. The phenotype varied according to genetic status, with non-desmosomal male patients showing lower left ventricular (LV) systolic function. LV fibrosis was similar between groups, but distribution in non-desmosomal patients was frequently located at the posterolateral LV wall; a characteristic LV subepicardial circumferential LGE pattern was significantly associated with ARVC/D caused by desmin mutation. Histological analysis showed increased fibrillar connective tissue and intercellular space in all the samples. Conclusion: Desmosomal and non-desmosomal mutation carriers showed different morphofunctional features but similar LV LGE presence. DES mutation carriers can be identified by a specific and extensive LV subepicardial circumferential LGE pattern. Further studies should investigate the specificity of LGE in ARVC/D.

5 February 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SGShinya Goto
Shinya Goto
PAPantep Angchaisuksiri
Pantep Angchaisuksiri
JBJean‐Pierre Bassand
Jean‐Pierre Bassand
ACA. John Camm
A. John Camm
HDHelena Dominguez
Helena Dominguez
IKI. Kobielusz‐Gembala
I. Kobielusz‐Gembala
Background: Using data from the GARFIELD ‐ AF (Global Anticoagulant Registry in the FIELD –Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results: GARFIELD ‐ AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013–2016) were classified with no, mild, or moderate‐to‐severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate‐to‐severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA 2 DS 2 ‐ VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate‐to‐severe CKD were independent risk factors for all‐cause mortality. Moderate‐to‐severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new‐onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate‐to‐severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P =0.001). Conclusions: In GARFIELD ‐ AF , moderate‐to‐severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate‐to‐severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.

1 June 2020 in Heart Rhythm
Verified
Journal Article
Closed access
FDFernando Dominguez
Fernando Dominguez
EZEsther Zorio
Esther Zorio
JJJuan Jimenez-Jaimez
Juan Jimenez-Jaimez
RSRafael Salguero-Bodes
Rafael Salguero-Bodes
RZRobert Zwart
Robert Zwart
PGPablo Garcia-Pavia
Pablo Garcia-Pavia

28 May 2021 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
MRMaria Alejandra Restrepo-Cordoba
Maria Alejandra Restrepo-Cordoba
KWKarim Wahbi
Karim Wahbi
AFAnca R. Florian
Anca R. Florian
JJJuan Jiménez Jáimez
Juan Jiménez Jáimez
Luisa PolitanoLuisa Politano
Luisa Politano
RSRafael Salguero-Bodes
Rafael Salguero-Bodes

30 November 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
ACAnabel Cámara
Anabel Cámara
FPFrancesca Perin
Francesca Perin
MRMarcos Rubio-Alarcón
Marcos Rubio-Alarcón
MDMaría Dago
María Dago
TCTeresa Crespo
Teresa Crespo
EDEva Delpón
Eva Delpón
In a family with inappropriate sinus tachycardia (IST), we identified a mutation (p.V240M) of the hyperpolarization-activated cyclic nucleotide–gated type 4 (HCN4) channel, which contributes to the pacemaker current (I f ) in human sinoatrial node cells. Here, we clinically study fifteen family members and functionally analyze the p.V240M variant. Macroscopic (I HCN4 ) and single-channel currents were recorded using patch-clamp in cells expressing human native (WT) and/or p.V240M HCN4 channels. All p.V240M mutation carriers exhibited IST that was accompanied by cardiomyopathy in adults. I HCN4 generated by p.V240M channels either alone or in combination with WT was significantly greater than that generated by WT channels alone. The variant, which lies in the N-terminal HCN domain, increased the single-channel conductance and opening frequency and probability of HCN4 channels. Conversely, it did not modify the channel sensitivity for cAMP and ivabradine or the level of expression at the membrane. Treatment with ivabradine based on functional data reversed the IST and the cardiomyopathy of the carriers. In computer simulations, the p.V240M gain-of-function variant increases I f and beating rate and thus explains the IST of the carriers. The results demonstrate the importance of the unique HCN domain in HCN4, which stabilizes the channels in the closed state.